PSI Recommendation

PSI Mass Spectrometry and Proteomics Informatics Working Groups

Status: FINAL

Juan Antonio Vizcaíno, EMBL-EBI

Eric W. Deutsch, Institute for Systems Biology

Pierre-Alain Binz, CHUV Lausanne University Hospital

Ryan T. Fellers, Northwestern University

Anthony J. Cesnik, Stanford University

Joshua A. Klein, Boston University

Tim Van Den Bossche, Ghent University

Ralf Gabriels, Ghent University

Yasset Perez-Riverol, EMBL-EBI

Jeremy Carver, University of California San Diego

Shin Kawano, Toyama University of International Studies

Benjamin Pullman, University of California San Diego

Nuno Bandeira, University of California San Diego

Paul M. Thomas, Northwestern University

Richard D. LeDuc, Northwestern University

February 3, 2022

**ProForma 2.0 (Proteoform and Peptidoform Notation)**

Status of this document

This document provides information to the proteomics community about a proposed extension of the standard proteoform notation called ProForma. Distribution is unlimited.

Version Draft 15 - this is a draft of version 2.0.0

# Abstract

The Human Proteome Organisation (HUPO) Proteomics Standards Initiative (PSI) defines community standards for data representation in proteomics to facilitate data comparison, exchange and verification. This document presents a specification for a proteoform and peptidoform notation, which is based on the ProForma notation [1], previously published by the Consortium for Top-Down Proteomics.

Further detailed information, including any updates to this document, implementations, and examples is available at <http://psidev.info/proforma>.

Contents

[Abstract 1](#_Toc89071607)

[1. Introduction 4](#_Toc89071608)

[1.1 Description of the need 4](#_Toc89071609)

[1.2 Requirements 4](#_Toc89071610)

[1.3 Issues to be addressed 5](#_Toc89071611)

[2. Notational Conventions 5](#_Toc89071612)

[3. The Proteoform and Peptidoform Notation Definition 5](#_Toc89071613)

[3.1 The documentation 5](#_Toc89071614)

[3.2 Relationship to other specifications 6](#_Toc89071615)

[4. The Basic Form of the Proteoform and Peptidoform Notation 7](#_Toc89071616)

[4.1 The canonical amino acid sequence 7](#_Toc89071617)

[4.2 Generic representation of protein modifications 8](#_Toc89071618)

[4.2.1 Controlled vocabulary or ontology modification names 8](#_Toc89071619)

[4.2.1.1 Definition of the Unimod modification name 9](#_Toc89071620)

[4.2.2 Controlled vocabulary or ontology protein modification accession numbers 9](#_Toc89071621)

[4.2.3 Support for cross-linkers 10](#_Toc89071622)

[4.2.3.1 Crosslink notation (within the same peptide) 10](#_Toc89071623)

[4.2.3.2 Representing inter-chain crosslinks 11](#_Toc89071624)

[4.2.3.3 Representing disulfide linkages 11](#_Toc89071625)

[4.2.4 Representation of branched peptides 12](#_Toc89071626)

[4.2.5 Representation of glycans using the GNO ontology as CV 12](#_Toc89071627)

[4.2.6 Delta mass notation 13](#_Toc89071628)

[4.2.7 Specifying a gap of known mass 14](#_Toc89071629)

[4.2.8 Support for elemental formulas (e.g. for representing small molecular substructures or functional groups) 14](#_Toc89071630)

[4.2.9 Representation of glycan composition 15](#_Toc89071631)

[4.2.10 Best practices on the use of protein modifications 16](#_Toc89071632)

[4.3 Representation of special cases: N-terminal, C-terminal and labile protein modifications 16](#_Toc89071633)

[4.3.1 N-terminal and C-terminal modifications 16](#_Toc89071634)

[4.3.2 Labile modifications 16](#_Toc89071635)

[4.4 Support for the representation of ambiguity in the modification position 17](#_Toc89071636)

[4.4.1 Unknown modification position 17](#_Toc89071637)

[4.4.2 Indicating a possible set of modification positions 18](#_Toc89071638)

[4.4.3 Representing ranges of positions for the modifications 18](#_Toc89071639)

[4.4.4 Indicating modification position preference and localisation scores 19](#_Toc89071640)

[4.4.5 Representing scoring for ranges of positions for a modification 19](#_Toc89071641)

[4.5 Representation of multiple modifications in the same amino acid residue 19](#_Toc89071642)

[4.6 Representation of global modifications 20](#_Toc89071643)

[4.6.1 Use Case 1: Representation of isotopes 20](#_Toc89071644)

[4.6.2 Use Case 2: Fixed protein modifications 20](#_Toc89071645)

[4.7 Representation of amino acid sequence ambiguity 21](#_Toc89071646)

[4.8 The information tag 21](#_Toc89071647)

[4.9 Support for the joint representation of experimental data and its interpretation 22](#_Toc89071648)

[5. Pending Issues - Future developments 23](#_Toc89071649)

[5.1 Representation of cyclic peptides 23](#_Toc89071650)

[5.2 Representation of ambiguity when different glycans are attached to the same amino acid sequence 24](#_Toc89071651)

[5.3 Representation of rare amino acids not supported by the one letter code 25](#_Toc89071652)

[5.4 Representation of average masses 25](#_Toc89071653)

[5.5 Representation of lipids 25](#_Toc89071654)

[5.6 Distribution of isotopes in the sequence 26](#_Toc89071655)

[5.7 Representation of molecular formula 26](#_Toc89071656)

[5.8 Representation of an overlapping range of possible modification positions 26](#_Toc89071657)

[5.9 Representation of ambiguous crosslinker modification positions 26](#_Toc89071658)

[5.10 Metadata related to ProForma entries 26](#_Toc89071659)

[5.11 Representation of sequences coming from non-mass spectrometry-based proteomics approaches 27](#_Toc89071660)

[6. Appendix I. Levels of Compliance 28](#_Toc89071661)

[7. Appendix II: Extensions to improve the representation of PSMs in mass spectra 30](#_Toc89071662)

[7.1 Representation of the ion charges 30](#_Toc89071663)

[7.2 Representation of multiple peptidoform assignments in chimeric spectra 30](#_Toc89071664)

[8. Appendix III. Glossary of terms used in the specification 32](#_Toc89071665)

[9. Authors Information 36](#_Toc89071666)

[10. Contributors 37](#_Toc89071667)

[11. Intellectual Property Statement 38](#_Toc89071668)

[12. Copyright Notice 38](#_Toc89071669)

[13. Glossary 39](#_Toc89071670)

[14. References 39](#_Toc89071671)

# Introduction

## **Description of the need**

Protein and peptide sequences are usually represented using a string of amino acids using a well-known one letter code endorsed by the IUPAC (see e.g. <https://wissen.science-and-fun.de/chemistry/biochemistry/iupac-one-letter-codes-for-bioinformatics/>). Representing all the possible variations of a protein or peptide primary structure, including both artefactual and post-translational modifications (PTMs) of peptides and proteins is less clear. For example, the Consortium for Top-Down Proteomics (CTDP) has introduced a standard proteoform notation format called ProForma [1, 2] for writing the primary structures of fully characterized proteoforms [3]. Proteoforms comprise protein species that include variations arising from genetic, transcriptomic, translational, post-translational, and artefactual (e.g., during sample processing) sources. ProForma specifically focuses on representing post-translational modifications of endogenous and artefactual sources. Briefly, ProForma describes proteoforms as the amino acid sequences (the one-letter code representation) complemented with information on any modifications (of a known identity or via unidentified mass shifts) given in brackets following certain amino acids.

Despite its suitability to support a wide range of possible use cases, the original ProForma notation had some limitations. Additionally, the Proteomics Standards Initiative (PSI) has developed a format called PEFF (PSI Extended FASTA Format, <http://www.psidev.info/peff>) [4]. Although PEFF’s primary intended use is for representing search databases for optimising proteomics analyses, PEFF can also be used to represent proteoforms [3] (see more details in Section 4). Therefore, there are multiple ways of encoding protein modifications and extended discussion has taken place to achieve a consensus. A comprehensive standard notation for proteoforms, as well as for their peptidic counterparts –peptidoforms (term introduced in [5])– is then required for the community, so that it can enhance the current description or be newly embedded in many relevant PSI (and potentially other) file formats.

The format specification presented here, ProForma 2.0, represents the consensus between both groups, CTDP and PSI, for the enhanced standard representation of proteoforms and peptidoforms. Compared to the original ProForma notation, it aims to support a broader variety of peptidomics and proteomics approaches, including bottom-up (focused on peptides/peptidoforms) and middle/top-down (focused on proteins/proteoforms) approaches [6]. The name of the notation, ProForma 2.0, derives from the original ProForma notation introduced by CTDP. For simplicity, going forward we will refer to this extended notation as ProForma.

## **Requirements**

The main eight requirements to be fulfilled for a proteoform and peptidoform notation are:

* It MUST be a string that is human readable, so it can be generally understood by human individuals.
* It MUST be machine parsable. Other variants of this notation will not be supported computationally, although they could be ‘human readable.’
* It MUST be able to support the encoding of amino acid sequences and protein modifications.
* It MUST be able to support the main use cases needed by the proteomics community as a whole, including both bottom-up (focused on peptides/peptidoforms) and middle/top-down (focused on proteins/proteoforms) approaches.
* It MUST be flexible to accommodate different “flavours” of notations, considering common current use.
* It MUST be compatible with existing PSI file formats, where it could be used.
* It MUST be able to capture ambiguity in the position of the modified sites.
* It MUST be able to evolve, so new use cases can be added iteratively in the future.

Several of these requirements, particularly the first three, coincide with those of the original ProForma notation [2]. The fourth requirement was present in the ProForma notation description, but now includes support for the bottom-up proteomics-specific entities, i.e., peptides, whereas the original ProForma notation exclusively targeted whole proteoforms. The final four requirements are new.

## **Issues to be addressed**

The main issues to be addressed by ProForma are:

* It MUST be able to represent peptidoforms and proteoforms in a consistent and reproducible way, considering the different ways of representing protein modifications.
* It MUST be able to be used jointly with the Universal Spectrum Identifier (USI), to represent peptide-spectrum matches (PSMs), and to represent proteoform-spectrum matches (PrSMs).

# Notational Conventions

The key words “MUST”, “MUST NOT”, “REQUIRED”, “SHALL”, “SHALL NOT”, “SHOULD”, “SHOULD NOT”, “RECOMMENDED”, “MAY”, and “OPTIONAL” are to be interpreted as described in RFC 2119 (2).

# The Proteoform and Peptidoform Notation Definition

## **The documentation**

The documentation of the ProForma Notation for proteoform and peptidoforms is divided into several components. All components in their most recent form are available at the HUPO-PSI website (<http://psidev.info/proforma>) and at the ProForma GitHub page (<https://github.com/HUPO-PSI/ProForma/>).

* Main specification document (this document).
* List of current implementations with examples.
  + C# ProForma Parser: <https://github.com/topdownproteomics/sdk>
  + USI implementation (Institute for Systems Biology, <http://proteomecentral.proteomexchange.org/usi/>).

## **Relationship to other specifications**

The format specification described in this document is not being developed in isolation; indeed, it is designed to be complementary to, and thus used in conjunction with, several existing and emerging models. Related specifications include the following:

1. *PSI Universal Spectrum Identifier* (<http://www.psidev.info/USI>). The PSI Universal Spectrum Identifier is designed to provide a universal mechanism for referring to a specific spectrum in public repositories. It can optionally include an interpretation of the spectrum using the notation described in this specification. Displayers of USIs MAY use any of the supported ProForma notations.
2. *mzSpecLib, the PSI spectrum library format* (<http://psidev.info/mzSpecLib>). The PSI spectrum library format is being developed as a standard mechanism for storing spectrum libraries. Identified spectra of modified peptides, will have to include the modification information, potentially in this ProForma notation. Furthermore, many spectrum library entries are derived from multiple spectra, and this provenance will be referenced using USIs.
3. *PROXI* (<http://www.psidev.info/proxi>). The Proteomics Expression Interface being developed by the PSI is a standardized API by which mass spectrometry proteomics information can be exchanged. References to individual spectra will be made via USIs.
4. *PEFF* (<http://www.psidev.info/peff>).Although it is not its main intended use, the PSI Extended Fasta Format enables the representation of proteoforms [4]. However, PEFF was not designed for the representation of the (potentially much shorter) peptidoforms. Additionally, PEFF 1.0 supports formally only a subset of the use cases outlined in this specification. Another key difference is that each proteoform instance in PEFF requires a FASTA header, whereas this is not required in ProForma.
5. *ProForma* (<http://psidev.info/proforma>)*.* ProForma Proteoform Notation version 1, which enables the representation of proteoforms (<https://topdownproteomics.github.io/ProteoformNomenclatureStandard/>), developed by the CTDP [1]. This specification is subsumed by this new version 2 ProForma specification.

# The Basic Form of the Proteoform and Peptidoform Notation

The ProForma notation is a string of characters that represent linearly one or more peptidoform/proteoform primary structures with possibilities to link peptidic chains together. It is not meant to represent higher order structures.

ProForma is case insensitive. However, within the data that follows the different keys, capitalisation may be important. In that case, capitalisation sensitivity is the decision of the supported CVs/ontologies.

Since ProForma MAY be used to represent both peptidoforms and proteoforms, there is currently no limit in its maximum length. Line breaks MUST NOT be used. However, non-ASCII characters are also allowed since non-ASCII characters can be included in the supported ontologies and controlled vocabularies (CVs).

If implementers want to add any metadata (e.g. date of creation, software, version of ontologies, etc) to ProForma entities, the way to do it in this version would be to use the INFO tag.

Due to the multiple use cases supported in this specification, it is not expected that all implementers can provide support to all the supported features from ProForma. To facilitate adoption and separate some of the use cases, there are multiple “levels of compliance” and extensions for ProForma, which are summarised in Appendix I.

## **The canonical amino acid sequence**

Amino acid sequences are represented by strings of amino acids represented as characters using the one letter code endorsed by the IUPAC (<http://publications.iupac.org/pac/1984/pdf/5605x0595.pdf>

and <https://wissen.science-and-fun.de/chemistry/biochemistry/iupac-one-letter-codes-for-bioinformatics/>). There are also letters for representing ambiguous and/or unusual amino acids (see <http://www.insdc.org/documents/feature_table.html#7.5.3>), which are used in some UniProt entries. Some examples are:

- B: Aspartic Acid or Asparagine

- Z: Glutamic Acid or Glutamine

- J: Leucine or Isoleucine

- U: Selenocysteine

- O: Pyrrolysine

- X: Any amino acid (see also Section 4.2.6 Specifying a gap of known mass, for the use of X). We note that the character X itself is assigned zero mass in this notation.

The representation of non-linear peptides is NOT formalised in this version of ProForma. See the section 5.3 (“Representation of cyclic peptides”) in *Section 5: Pending Issues*, for possible ways to represent them.

## **Generic representation of protein modifications**

It has been decided that multiple formats and reference systems must be supported, because some flexibility is required. The same approach is followed for both artefactual protein modifications and natural PTMs. Square brackets MUST be used to represent them when the position is unambiguous. They are located after the character representing the modified amino acid. If there is ambiguity in the position of the protein modification, different rules apply (see section 3.3.4).

Five different reference systems for protein modifications are supported including the following CVs and/or ontologies:

- Unimod (<http://www.unimod.org/>).

- PSI-MOD (<https://github.com/HUPO-PSI/psi-mod-CV>).

- RESID (<https://proteininformationresource.org/resid/>). Although RESID is included in PSI- MOD, this reference system is still used in the top-down community.

- XL-MOD (<https://raw.githubusercontent.com/HUPO-PSI/mzIdentML/master/cv/XLMOD.obo>) MUST be used for the representation of cross-linkers.

- GNO (Glycan Naming Ontology, <https://www.ebi.ac.uk/ols/ontologies/gno>).

### **Controlled vocabulary or ontology modification names**

The names from different CV or ontology terms MAY be used to represent protein modifications. The two main reference systems used are Unimod and PSI-MOD. However, to facilitate differentiation between reference systems for readers, the names coming from other three supported CV/ontology MUST be preceded by a letter and colon, indicating the originating CV/ontology. In the case of Unimod and PSI-MOD, the use of prefixes is optional.

Examples of proper modification name usage:

- Unimod: U (optional)

- PSI-MOD: M (optional)

- RESID: R (mandatory)

- XL-MOD: X (mandatory)

- GNO: G (mandatory)

EM[Oxidation]EVEES[Phospho]PEK (example using Unimod names)

EM[L-methionine sulfoxide]EVEES[O-phospho-L-serine]PEK (example using PSI-MOD names)

EM[R: L-methionine sulfone]EVEES[O-phospho-L-serine]PEK

EMEVTK[X:DSS#XL1]SESPEK (see Section 4.2.3)

In the case of GNO, the use of accession numbers is preferred since accession numbers and names are often the same. Example:

NEEYN[GNO:G59626AS]K is preferred over NEEYN[G:G59626AS]K

Prefixes can still be used for Unimod and PSI-MOD names (but it is not included in basic support, see Appendix I):

EM[U:Oxidation]EVEES[U:Phospho]PEK

EM[M:L-methionine sulfoxide]EVEES[M:O-phospho-L-serine]PEK

If prefixes are not used for CV/ontology term names, different CVs/ontologies in the same ProForma instance SHOULD NOT be mixed:

EM[U:Oxidation]EVEES[M:O-phospho-L-serine]PEK

EM[Oxidation]EVEES[O-phospho-L-serine]PEK -> Different CVs/ontologies SHOULD NOT be used.

Special characters do not need to be escaped. The only restriction is that unpaired bracket characters MUST NOT be used. Example of properly paired internal brackets:

EM[Oxidation]EVE[Cation:Mg[II]]ES[Phospho]PEK

For different reference systems not supported explicitly, the tag ‘INFO’ MUST be used (see Section 4.7).

#### Definition of the Unimod modification name

The Unimod OBO file SHOULD be used: <http://www.unimod.org/obo/unimod.obo>. Within this file, term names are found in the “name” tag. These terms differ in the Unimod web interface (<http://www.unimod.org/>). There, the equivalent to the “name” field in the OBO file is the “PSI-MS Name” column, if not empty (if there is a value). If the “PSI-MS Name” field is empty, the “interim name” is used. Unimod synonyms are currently NOT supported, as they are provided inconsistently.

### **Controlled vocabulary or ontology protein modification accession numbers**

In case accession numbers from the supported CVs/ontologies are used, to report protein modifications full accession numbers MUST be used in all cases (no abbreviations in the names of the ontologies/CVs are allowed). The supported names are:

- Unimod: UNIMOD

- PSI-MOD: MOD

- RESID: RESID

- XL-MOD: XLMOD

- GNO: GNO

Examples of proper accession number usage:

EM[MOD:00719]EVEES[MOD:00046]PEK

EM[UNIMOD:35]EVEES[UNIMOD:56]PEK

EM[RESID:AA0581]EVEES[RESID:AA0037]PEK

The following examples are incorrect:

EM[M:00719]EVEES[M:00046]PEK

EM[U:35]EVEES[U:56]PEK

EM[R:AA0581]EVEES[R:AA0037]PEK

### **Support for cross-linkers**

Support for cross-linkers is possible by using the XL-MOD CV. It is acknowledged that the current version of ProForma does not provide support for all possible use cases involving cross-linked peptides. In the future, it is expected that a specific extension for this type of information can be developed.

Using the XL-MOD CV, crosslinked sites MUST represented immediately following the modification notation using the prefix #XL, followed by an arbitrary label consisting of alphanumeric characters ([A-Za-z0-9]+ in regular expression notation). Cross-linker modification notations MUST be mentioned once only.

Any annotation made with the symbol # represents a way of linking different locations within the amino acid sequence. In ProForma 2.0 it is used for representing cross-linkers, branched peptides and for grouping protein modifications (including glycans) to represent ambiguity.

#### Crosslink notation (within the same peptide)

Cross-linker modification notations MUST be mentioned once only. This example shows a DSS crosslink between two lysines:

EMEVTK[XLMOD:02001#XL1]SESPEK[#XL1]

This second example shows a DSS crosslink between two lysines and an EDC cross-link between two other lysines:

EMK[XLMOD:02000#XL1]EVTKSE[XLMOD:02010#XL2]SK[#XL1]PEK[#XL2]AR

A “dead end” crosslink happens regularly with bifunctional crosslinkers when one side attaches and the other hydrolyses before attaching. These modifications are annotated at only one site.

EMEVTK[XLMOD:02001#XL1]SESPEK

EMEVTK[XLMOD:02001]SESPEK

#### Representing inter-chain crosslinks

Inter-protein or inter-chain connections are supported using // to separate the crosslinked peptides. This notation is similar to IUPAC condensed notation for inter-protein connections.

SEK[XLMOD:02001#XL1]UENCE//EMEVTK[XLMOD:02001#XL1]SESPEK

SEK[XLMOD:02001#XL1]UENCE//EMEVTK[#XL1]SESPEK

It is acknowledged by the authors that more complex scenarios are possible when representing inter-chain crosslinks, including a higher number of linked peptides, directionality, etc. It is envisioned that when these use cases become a clear requirement in the future, a dedicated working group can extend these guidelines.

#### Representing disulfide linkages

Disulfide bonds may be represented using four possible notations:

(i) Using the PSI-MOD term for “L-cystine (cross link)” (MOD:00034) to explicitly describe the cross-link using the cross-linking notation:

EVTSEKC[MOD:00034#XL1]LEMSC[#XL1]EFD

EVTSEKC[L-cystine (cross-link)#XL1]LEMSC[#XL1]EFD

There are more complex examples that are possible. For instance, another example with inter-chain disulfide bonds is insulin:

FVNQHLC[MOD:00034#XL1]GSHLVEALYLVC[MOD:00034#XL2]GERGFFYTPKA\\GIVEQC[MOD:00034#XL3]C[#XL1]TSIC[#XL3]SLYQLENYC[#XL2]N

As mentioned above, more complex scenarios are possible which will need to be resolved in future versions.

(ii) Using the XLMOD term XLMOD:02009 similarly to case (i) above:

EVTSEKC[XLMOD:02009#XL1]LEMSC[#XL1]EFD

EVTSEKC[X:Disulfide#XL1]LEMSC[#XL1]EFD

(iii) Using the PSI-MOD term for “half cystine” (MOD:00798) if the pairing is not known. Since the term is only for half the link, it must be specified on all involved sites with no group tag:

EVTSEKC[half cystine]LEMSC[half cystine]EFD

EVTSEKC[MOD:00798]LEMSC[MOD:00798]EFDEVTSEKC[MOD:00798]LEMSC[MOD:00798]EFD

(iv) Using the Unimod term for “Dehydro” (UNIMOD:374) to explicitly describe the cross-link using the cross-linking notation.

EVTSEKC[UNIMOD:374#XL1]LEMSC[#XL1]EFD

EVTSEKC[Dehydro#XL1]LEMSC[#XL1]EFD

### **Representation of branched peptides**

Branched peptides can be expressed using the same notation used for representing two cross-linked peptides, but using the term #BRANCH (see above). Examples:

a) ETFGD[MOD:00093#BRANCH]\\R[#BRANCH]ATER

b) Cross-linked via a sidechain:

AVTKYTSSK[MOD:00134#BRANCH]\\AGKQLEDGRTLSDYNIQKESTLHLVLRLRG-[#BRANCH]

Where a sidechain of a Lysine from peptide 1 is linked to the C-term of the peptide 2 via amidation (-H2O)

Graphical user interface, diagram, application

Description automatically generated

Taken from:

<https://www.news-medical.net/whitepaper/20180329/Synthesizing-Unsymmetrically-Branched-Peptides.aspx>

### **Representation of glycans using the GNO ontology as CV**

Glycans that are currently included in Unimod or PSI-MOD (individual or very short chains) MAY be represented that way. If the glycans are not included in either PSI-MOD or Unimod, the GNO ontology SHOULD be used. As mentioned above, the use of accession numbers is preferred since accession numbers and names are often the same.

Examples of proper glycan notation:

Encoding Hex 5 HexNAc 4 NeuAc 1:

NEEYN[GNO:G59626AS]K

Encoding Hex 8 HexNAc 2 and Hex 5 HexNAc 2:

YPVLN[GNO:G62765YT]VTMPN[GNO:G02815KT]NSNGKFDK

The same mechanisms for expressing labile modifications and ambiguity in the modification position applicable to other types of modifications SHOULD be used for glycans as well (see following sections, e.g. Sections 4.3.2 and 4.4).

There are more complex cases, where ambiguity can be caused by multiple combinations between labile and non-labile glycans attached to the same amino acid sequence. A possible mechanism to represent these more complex cases is available in Section 5 (*Pending issues*). A further limitation comes from the restricted set of glycans in GNO. We expect that these issues will be solved as the glyco(proteomics) community develops in the near future.

### **Delta mass notation**

In addition to using CV/ontologies names and/or accession numbers, mass differences (delta masses) MAY be used to represent protein modifications.

Delta masses SHOULD only be used when the protein modification cannot be represented using a CV/ontology (e.g., if software does not use ontologies/CVs), when the modification (or combination of modifications) is ambiguous (e.g., coming from open modification searches or de-novo approaches), or when it is unknown. Otherwise, protein modifications SHOULD be represented using Unimod, PSI-MOD, RESID, XL-MOD, or GNO CV parameters.

Mass differences MUST be expressed in Daltons between the coded amino acid and the observed mass. Positive mass shifts MUST be specified with a plus sign. Negative shifts MUST be specified with a negative sign. Monoisotopic masses MUST be used. There are two ways of representing delta masses:

A) Without using prefixes.

EM[+15.9949]EVEES[+79.9663]PEK

EM[+15.995]EVEES[-18.01]PEK

Interpretation of the actual delta masses is then left to the reader software.

B) Using prefixes for CVs/ontologies to provide more information.

If “canonical” delta masses are directly taken from a CV/ontology, the corresponding abbreviation to that CV/ontology MAY be used.

- Unimod: U

- PSI-MOD: M

- RESID: R

- XL-MOD: X

- GNO: G

Examples of delta masses corresponding to CV/ontology entries:

EM[U:+15.9949]EVEES[U:+79.9663]PEK

EM[U:+15.995]EVEES[U:+79.966]PEK

The notation also supports the encoding of experimentally observed delta masses. In those cases, the prefix “Obs” MUST be used. The number of significant figures included in the delta mass depends on the accuracy of the available data and SHOULD be used as is by interpreters. Example:

EM[U:+15.995]EVEES[Obs:+79.978]PEK

### **Specifying a gap of known mass**

This mechanism can be used to express a gap in the sequence of an unknown number of amino acids, but the corresponding mass difference is known. This is supported by the use of the character X followed by brackets indicating the total mass of the gap, meaning that the mass of X is actually zero.

Example of proper gap notation:

RTAAX[+367.0537]WT

### **Support for elemental formulas (e.g. for representing small molecular substructures or functional groups)**

A modification representing a small molecular substructure or a functional group can be described by a chemical formula. The descriptor “Formula” MUST be used. Only elemental formulas are supported. Example of proper chemical formula usage:

SEQUEN[Formula:C12H20O2]CE

SEQUEN[Formula:[13C2]CH6N]CE

As no widely accepted specification exists for expressing elemental formulas, we have adapted a standard with the following rules (taken from <https://github.com/rfellers/chemForma>):

Formula Rule 1

A formula will be composed of pairs of atoms and their corresponding cardinality (two Carbon atoms: C2). Pairs SHOULD be separated by spaces but are not required to be. Atoms and cardinality SHOULD NOT be. Also, the Hill system for ordering (<https://en.wikipedia.org/wiki/Chemical_formula#Hill_system>) is preferred, but not required.

Example: C12H20O2 or C12 H20 O2

Formula Rule 2

Cardinalities must be positive or negative integer values. Zero is not supported. If a cardinality is not included with an atom, it is assumed to be +1.

Example: HN-1O2

Formula Rule 3

Isotopes will be handled by prefixing the atom with its isotopic number in square brackets. If no isotopes are specified, previous rules apply. If no isotope is specified, then it is assumed the natural isotopic distribution for a given element applies.

Example: [13C2][12C-2]H2N

Example: [13C2]C-2H2N

SEQUEN[Formula:[13C2][12C-2]H2N]CE

(here 2 12C atoms are replaced by 2 13C atoms)

See in Section 5 (*Pending issues*) how this mechanism could be extended in the future to support more complex molecular formulas.

### **Representation of glycan composition**

Glycan residues (generic monosaccharides) can be represented using the descriptor “Glycan”. If glycan symbols conflict with themselves or element symbols in such a way that ambiguities occur, we will consider requiring spaces between 'atoms' (see Formula Rule #1).

Example: Hex2HexNAc

SEQUEN[Glycan:HexNAc1Hex2]CE

The supported list of monosaccharides in ProForma is included below. It is worth noting that the masses and elemental compositions included below for each monosaccharide are those resulting after each of them are condensed with the amino acid chain.

Hex: Hexose, 162.0528 Da, C6H10O5

HexNAc: N-Acetyl Hexose, 203.0793 Da, C8H13N1O5

HexS: Hexose Sulfate, 242.0096 Da, C6H10O8S1

HexP: Hexose Phosphate, 242.0191 Da, C6H11O8P1

HexNAcS: N-Acetyl Hexose Sulfate, 283.0361 Da, C8H13N1O8S1

dHex: Deoxy-Hexose, 146.0579 Da, C6H10O4

NeuAc: N-acetyl Neuraminic Acid / Sialic Acid, 291.0954 Da, C11H17N1O8

NeuGc: N-glycolyl Neuraminic Acid, 307.0903 Da, C11H17N1O9

Pen: Pentose, 132.0422 Da, C5H8O4

Fuc: Fucose, 146.0579 Da, C6H10O4 (a particular stereochemical assignment of dHex abundant in mammals)

However, we envision that more monosaccharides could be added once this specification document is formalised. An updated list of supported monosaccharides (in two different formats, obo and json) can be found at:

<https://github.com/HUPO-PSI/ProForma/tree/master/monosaccharides>

For other glycans not included there, a new CV term will need to be created, e.g. in PSI-MOD.

It is recognised that this mechanism is limited and can only support the most common glycans. It is envisioned that in the future, when this use case becomes a requirement, a dedicated working group can work in extending these specific guidelines. See Section 5 (*Pending issues*) for guidance on future extensions of this mechanism to support other macromolecules, e.g. lipids.

### **Best practices on the use of protein modifications**

In the same sequence, the same reference system SHOULD be used to represent the protein modifications. However, the delta mass notation (Section 4.2.5) MAY be combined with the other cases.

## **Representation of special cases: N-terminal, C-terminal and labile protein modifications**

### **N-terminal and C-terminal modifications**

The square brackets containing the modification MUST be located before the first amino acid in the sequence or after the last amino acid in the peptide sequence. In both cases, they are separated by a dash (-). Examples:

[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK

[iTRAQ4plex]-EM[U:Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]-[Methyl]

### **Labile modifications**

Labile modifications are those which are known to separate under certain experimental conditions during fragmentation and therefore are not visible in the fragmentation MS2 spectrum (i.e. the MS2 spectra are indistinguishable from spectrum not containing the modification). They are represented by curly brackets {}, not by square ones. As explained in Section 4.2.8, the prefix “Glycan:” needs to be added for each labile monosaccharide. Labile modification MUST be located before the first amino acid sequence and before N-terminal modifications, if applicable. Examples:

{Glycan:Hex}EM[U:Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]

{Glycan:Hex}[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]

{Glycan:Hex}[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]-[Methyl]

One can also express multiple labile modifications using the following notation:

{Glycan:Hex}{Glycan:NeuAc}EMEVNESPEK

## **Support for the representation of ambiguity in the modification position**

This notation is used to represent ambiguous modified sites, associated positions and associated probabilities or scores.

This notation is not yet supported for crosslinker modifications (see Section 5.9), except for the case of disulfide cross-linkers which may be represented with ambiguous position using the PSI-MOD term for “half-cystine” (MOD:00798), as noted in Section 4.2.3.3.iii.

### **Unknown modification position**

The positions of some modifications may be unknown. In this case, protein modifications are represented using square brackets that MUST be located on the left side of the amino acid sequence. The symbol ‘?’ is used to indicate that the actual position of the modification is unknown.

[Phospho]?EM[Oxidation]EVTSESPEK

In case of multiple modifications with an unknown location, two options are possible to represent them:

(i) Listing them separately as in this example of two phosphorylations:

[Phospho][Phospho]?[Acetyl]-EM[Oxidation]EVTSESPEK

(ii) Indicating the concrete modification only once but using the caret (^) symbol to represent the number of occurrences of the modification.

[Phospho]^2?[Acetyl]-EM[Oxidation]EVTSESPEK

N-terminal modifications MUST be the last ones written, just next to the amino acid sequence. For example:

Wrong: [Acetyl]-[Phospho]^2?EM[Oxidation]EVTSESPEK

Right: [Phospho]^2?[Acetyl]-EM[Oxidation]EVTSESPEK

### **Indicating a possible set of modification positions**

The position of a modification may be unknown but belong to a known set of possible sites. In this case, the possible positions for the modifications may be indicated. The rules that MUST be followed are:

(i) Groups of possible sites for a modification are represented immediately following the modification notation using the symbol #, followed by an arbitrary label consisting of alphanumeric characters ([A-Za-z0-9]+ in regular expression notation). Note that the label prefix #XL is a special case that MUST be reserved for crosslinkers only.

(ii) A single preferred location for the modification MUST be specified, so that the sequence can be easily rendered in visualization tools. The preferred location for the modification is indicated by the position of the modification notation in the amino acid sequence.

In this example, ‘#g1’ is used as the arbitrary label:

EM[Oxidation]EVT[#g1]S[#g1]ES[Phospho#g1]PEK

This is read as a named group 'g1' indicates that a phosphorylation exists on either T5, S6 or S8, and S8 is the preferred location because the notation ‘Phospho’ is placed at this position.

The following example is not valid because a single preferred location must be chosen for a modification:

EM[Oxidation]EVT[#g1]S[Phospho#g1]ES[Phospho#g1]PEK

### **Representing ranges of positions for the modifications**

Ranges of amino acids as possible locations for the modifications may be represented using parentheses within the amino acid sequence. Some examples:

PRT(ESFRMS)[+19.0523]ISK

PRT(EC[Carbamidomethyl]FRMS)[+19.0523]ISK

The caret symbol (^), which can be used to represent multiple instances of the same unlocalised modification before the N-terminal end of the amino acid sequence (Section 4.4.1), is not allowed within the amino acid sequence.

Overlapping ranges represent a more complex case and are not yet supported, and so, the following example would NOT be valid:

P(RT(ESFRMS)[+19.0523]IS)[+19.0523]K

### **Indicating modification position preference and localisation scores**

There are two options to represent this type of information. The values of the modification localisation scores can be indicated in parentheses within the same group and brackets.

Example of proper localisation score usage:

EM[Oxidation]EVT[#g1(0.01)]S[#g1(0.09)]ES[Phospho#g1(0.90)]PEK

Scores for the modification position can be expressed as probabilities and/or FLR (False Localisation Rate), but the actual meaning of the scores is not reported. The preferred location of the modification notation reflects the value of the scores. If there is a tie in the value of the localisation scores, one preferred position needs to be chosen by the writer.

An additional option to represent localisation scores is to leave the position of the modification as unknown using the ‘?’ notation but report the localisation modification scores at specific sites.

Example of proper usage of localisation scores with unknown modification site notation:

[Phospho#s1]?EM[Oxidation]EVT[#s1(0.01)]S[#s1(0.09)]ES[#s1(0.90)]PEK

### **Representing scoring for ranges of positions for a modification**

Ranges of amino acids as possible locations for the modifications may also be accompanied by scoring using the same notation. Some examples:

PRT(ESFRMS)[+19.0523#g1(0.01)]ISK[#g1(0.99)]

PR[#g1(0.91)]T(EC[Carbamidomethyl]FRMS)[+19.05233#g1(0.09)]ISK

## **Representation of multiple modifications in the same amino acid residue**

It is possible to represent two or more modifications on the same amino acid or group of amino acids. The caret symbol (^), which can be used to represent multiple instances of the same unlocalised modification before the N-terminal end of the amino acid sequence (Section 4.4.1.) is however not allowed within the amino acid sequence. No extra character is required. Example:

MPGLVDSNPAPPESQEKKPLK(PCCACPETKKARDACIIEKGEEHCGHLIEAHKECMRALGFKI)[Oxidation][Oxidation][half cystine][half cystine]

This would not be allowed:

MPGLVDSNPAPPESQEKKPLK(PCCACPETKKARDACIIEKGEEHCGHLIEAHKECMRALGFKI)[Oxidation]^2[half cystine][half cystine]

Currently, complex glycans are not explicitly supported (see Section 3.4). An alternative solution in those rare cases not involving glycans is to have a single PSI-MOD/Unimod entry for the combination of mods, which would need to be created in advance, if not yet available.

## **Representation of global modifications**

This mechanism MAY be used for modifications that apply to all relevant residues in the peptide/protein amino acid sequence. These modifications MAY be represented by the use of the characters “<” and “>” on the left side of the sequences. A couple of use cases are envisioned:

### **Use Case 1: Representation of isotopes**

This might be used in the case of synthetic peptides with 100% incorporation.

Example: Consider extension for 13C on all residues:

Carbon 13: <13C>ATPEILTVNSIGQLK

Nitrogen 15: <15N>ATPEILTVNSIGQLK

Deuterium: <D>ATPEILTVNSIGQLK

The representation of multiple isotopes is also possible. They can be located in any order.

Both Carbon 13 and Nitrogen 15: <13C><15N>ATPEILTVNSIGQLK

Distributions of isotope masses could be supported in future work.

### **Use Case 2: Fixed protein modifications**

This mechanism can be useful especially in the case of full proteoforms. The affected amino acid MUST be indicated using @. If more than one residue were affected, they MUST be comma separated. Examples:

<[S-carboxamidomethyl-L-cysteine]@C>ATPEILTCNSIGCLK

<[MOD:01090]@C>ATPEILTCNSIGCLK

<[Oxidation]@C,M>MTPEILTCNSIGCLK

Fixed modifications MUST be written prior to ambiguous and labile modifications, and similar to ambiguity notation, N-terminal modifications MUST be the last ones written, just next to the sequence.

The following examples would be valid:

<[MOD:01090]@C>[Phospho]?EM[Oxidation]EVTSECSPEK

<[MOD:01090]@C>[Acetyl]-EM[Oxidation]EVTSECSPEK

## **Representation of amino acid sequence ambiguity**

Ambiguity in the amino acid sequence needs to be represented in some cases, e.g. to represent sequence changes that do not change the mass of the peptidoform/proteoform, but are not known. One concrete example is the need to encode the results of *de novo* sequencing tools. The way to encode this information is to use a parenthesis and a quotation mark including the ambiguous sequence represented in a preferred way. Examples:

(?DQ)NGTWEM[Oxidation]ESNENFEGYM[Oxidation]K

(?N)NGTWEM[Oxidation]ESNENFEGYM[Oxidation]K

In both examples, both ambiguous amino acid sequences are DQ and N, respectively.

## **The information tag**

General information or comments can be encoded using the ‘info’ tag like:

ELV[INFO:AnyString]IS

ELV[info:AnyString]IS

The information represented in an ‘info’ tag is considered non-standard (e.g. any text besides unpaired brackets) and does not need to be parsed.

“Info” tags can be split using the pipe character. Example of proper ‘info’ tag usage:

ELVIS[Phospho|INFO:newly discovered]K

ELVIS[Phospho|INFO:newly discovered|INFO:really awesome]K

The following comment would be invalid because of an unpaired bracket:

ELVIS[Phospho|INFO:newly]discovered]K

As a concrete example of its use, “Info” tags can be used to provide metadata about ProForma entities (e.g. date of creation, version of Unimod used, software used for creating it, and many others):

ELVIS[Phospho|INFO:newly discovered|INFO:Created on 2021-06]K

ELVIS[Phospho|INFO:newly discovered|INFO:Created by software Tool1]K

## **Support for the joint representation of experimental data and its interpretation**

The pipe character “|” is used to represent protein modifications simultaneously with CV/ontology names and/or accession numbers, and delta masses. As explained in Section 4.2.6, Delta mass notation, it is possible to represent both canonical delta masses and experimental observations, allowing the representation of both interpretation (using CV/ontology names/accession numbers) and experimental observations (delta masses).

Examples:

ELVIS[U:Phospho|+79.966331]K

Showing both the interpretation and measured mass:

ELVIS[U:Phospho|Obs:+79.978]K

Other combinations between CV/ontology names, accession numbers, and delta masses using synonyms are allowed, though they MUST be synonymous terms. Some examples:

ELVIS[Phospho|O-phospho-L-serine]K

ELVIS[UNIMOD:21|MOD:00046]K

ELVIS[UNIMOD:21|Phospho]K

ELVIS[Phospho|O-phospho-L-serine|Obs:+79.966]K

Ambiguous cases are also allowed because they can be used to represent “comparable” information.

ELVIS[Obs:+79.966|Phospho|Sulfo]K

Highly different modifications SHOULD NOT be joined as it would be difficult for readers to correctly interpret. It is however acknowledged that readers can choose to implement the parsing in different ways. Some tools may always take CV terms, others could take delta masses, and so on.

# Pending Issues - Future developments

Additionally, there are several use cases that are NOT currently supported in the current version of the specification. These complications are left open in version 2.0 of the specification and will ideally be addressed in future versions, after the community has gained more experience with the common cases. The objective here is to document those cases appropriately and propose some possible solutions for representing the information in future versions of ProForma.

## **Representation of cyclic peptides**

Cyclic peptides are only currently supported if they can be represented using the supported CVs/ontologies for protein modifications. The following examples represent possible ways to represent cyclic peptides, but these solutions need to be formalised and PSI-MOD modifications created.

1) Cyclic peptide with C- and N-termini bound together at the peptide backbone level

Kalata B1 (PubChemID: 46231131, UniProtKB: P56254)

[*MOD:nnnnnn#*XL1]-RNGLPVCGETCVGGTCNTPGCTCSEPVCT-[#XL1]

where *MOD:nnnnnn* would be a new PSI-MOD term to represent backbone cyclisation involving the amidation between a C-terminal carboxylate and a N-terminal amine, with mass difference of O-1H-2 (-18 Da).

2) Cyclic peptide with C- and N-termini bound together at the peptide backbone level with 3 disulfide bonds

Retrocyclin 1 (PubChem ID 16130540). The exact structure is the following:

<https://pubchem.ncbi.nlm.nih.gov/compound/Retrocyclin-1#section=Biologic-Description&fullscreen=true>

[*MOD:nnnnnn*#XL1]-RC[MOD:00798.DS1]IC[MOD:00798.DS2]GRGIC[MOD:00798.DS2]RC[MOD:00798.DS1]IC[MOD:00798.DS3]GRGIC[MOD:00798.DS3]-[*#*XL1]

where *MOD:nnnnnn* would be a new PSI-MOD term to represent backbone cyclisation involving the amidation between a C-terminal carboxylate and a N-terminal amine, with a mass difference of O-1H-2 (-18 Da).

3) Cyclic peptide with C-terminal COOH condensed to a sidechain NH2

3a) peptide with no other PTM

LEIK[N6-(L-asparagyl)-L-lysine#XL1]KIPHDN[#XL1]

3b) A real case scenario: Topitracin (PubChem ID:6474109)

[[N-[2-[1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-Leucine]-LE[D-Glutamic acid]IK[M:N6-(L-asparagyl)-L-lysine#XL1]K[M:D-Ornithine]I[M:D-alloisoleucine]P[D-Phenylalanine]HD[M:D-Aspartic acid]N[#XL1]

## **Representation of ambiguity when different glycans are attached to the same amino acid sequence**

Multiply glycosylated peptides, especially under vibrational/collisional dissociation, may fragment in ways that allow sequencing the peptide backbone without completely characterizing the glycan sites. Instead, only the aggregate composition can be determined based on the precursor peptide mass. In such cases, only the glycosylation may be known, by motif for N-glycan or there may be several possible sites. Alternatively, the total number of glycosylation sites may be unknown (O-glycans), with the aggregate glycan composition may be spread across positions in unknown proportions.

There is a need to express that a site is a possible glycosylation site as well as a mechanism to express the total amount of glycan composition shared across these sites. The latter is achieved by using a labile modification to prefix the total composition. There are multiple proposals for expressing putative site assignment:

Proposal 1. Use PSI-MOD glycosylated residue modifications.

{Glycan:Hex 10 HexNAc 4}YPVLN[MOD:00006]VTMPN[MOD:00006]NSNGKFDK

This peptide hosts two N-glycans, where the glycan class is known from the required motifs on the sequence, and that it is multiply glycosylated because no single N-glycan with the aggregate composition is biosynthetically feasible. This proposal denotes the inferred glycosylation sites using the PSI-MOD “N-glycosylated residue” term. This forces the reader to treat this group differently, where the modification is inferred to be the labile glycan modification and that the modification may be split amongst each site, assigning zero or more monosaccharides to each group position.

Pros:

* Conveys extra metadata about the glycan type
* Uses an existing term

Cons:

* Introduces new semantics for a modification that is not explicitly conveyed notationally, namely that this modification is not observable, but just encodes positional information.
* For complex and ambiguous O-glycopeptides, this method would pull double-duty with ambiguity notation.

Proposal 2. Use ambiguity groups.

{Glycan:Hex 10 HexNAc 4}YPVLN[#g1]VTMPN[Glycan#g1]NSNGKFDK

The same case with Proposal 1, but instead of adding extra baggage to an existing term, this proposal uses ambiguity groups to denote possible positions, and mark one group with a new “Glycan” key, which adds the same labile modification inference step.

Pros:

* Uses an ambiguity-specific mechanism to signal ambiguity.

Cons:

* Adds a new component to ambiguity group interpretation that parsers must now be prepared to handle.
* No ability to communicate glycan type at the site level.

A complex O-glycopeptide example

{Glycan:Hex 5 HexNAc 5}PEPSTAT[Glycan#g1]IS[#g1]T[#g1]ICS[#g1]S[#g1]T[#g1]RIKES[#g1]IT[#g1]ES[#g1]

Fragmentation may demonstrate that some S/T residues are not putative sites, while the distribution of glycan composition is still not known amongst the remaining sites. The true solution might be:

PEPSTATISTICS[Glycan:HexNAc Hex]S[Glycan:HexNAc Hex]TRIKES[Glycan:HexNAc Hex]IT[Glycan:HexNAc Hex]ES[Glycan:HexNAc Hex]

Or PEPSTATISTICSS[Glycan:HexNAc 2 Hex 2]TRIKES[Glycan:HexNAc Hex]IT[Glycan:HexNAc Hex]ES[Glycan:HexNAc Hex], or any permutation thereof.

Proposal 3. Use cross-linking-like notation

{Glycan:Hex 10 HexNAc 4.G1}YPVLN[Glycan:#G1]VTMPN[Glycan:#G1]NSNGKFDK

The only differentiating feature of this proposal from Proposal 2 is that it isolates the notational change solely within the Glycan tag handling, which reduces the burden on implementers who do not want to support glycosylation.

## **Representation of rare amino acids not supported by the one letter code**

This use case is currently not supported. These SHOULD be handled through their representations in one of the supported ontologies/CVs.

## **Representation of average masses**

During the development of the format, it was acknowledged that, in the case of top-down proteomics approaches, there could be cases where monoisotopic masses are unknown, and then average masses need to be used. At the moment, monoisotopic masses are the only ones formally allowed, but this MAY have to change in future changes.

## **Representation of lipids**

These SHOULD be handled through their representations in one of the supported ontologies/CVs. However, a similar mechanism to the one described in Section 4.2.8, Representation of glycan composition, could be implemented for lipid molecules.

Examples:

SEQUEN[Lipid:OleicAcid]CE

SEQUEN[Lipid:PalmiticAcid]CE

It is envisioned that when this use case becomes a clear requirement in the future, a dedicated working group can extend these specific guidelines.

## **Distribution of isotopes in the sequence**

The representation of the distributions of isotopes for global modifications (Section 4.6) is not supported in the current version of the specification. A mechanism will need to be envisioned to support this use case in future versions.

## **Representation of molecular formula**

Elemental formulas are supported by the current version of ProForma (Section 4.2.7), and molecular formulas may be supported in the future if it would prove helpful. For example, specifying branching in a PTM structure. A molecular formula may include repeated (condensed) sections using parentheses and an extra cardinality.

Examples:

CH3(CH2)4CH3

SEQUEN[Formula:CH3(CH2)4CH3]CE

## **Representation of an overlapping range of possible modification positions**

Notation of ambiguous localization currently supports non-overlapping ranges. A possible representation of overlapping ranges, that may be considered in the future, uses a grouping tag for both parentheses.

Examples:

PROT([#g1]EOC[Carbamidomethyl]FORMS)[+19.0523#g1]ISK

PR([#g1]OT([#g2]EOC[Carbamidomethyl]FOR)[+19.0523#g1]MS)[+19.0523#g2]ISK

PROT([#g1]([#g2]EOC[Carbamidomethyl]FORMS)[+19.0523#g2]IS)[+19.0523#g1]K

## **Representation of ambiguous crosslinker modification positions**

Notation for ambiguous crosslinker modification positions is not supported in this version of ProForma but may be supported in the future.

## **Metadata related to ProForma entries**

At present, metadata related to ProForma entries (e.g. date of creation, software, version of ontology used, etc) cannot be provided in a standardised manner. The creation of an additional metadata file could be considered in future versions.

## **Representation of sequences coming from non-mass spectrometry-based proteomics approaches**

The Proforma notation could be made compatible with non-mass spectrometry proteomics approaches, such as nanopore and Edman-based sequencing, and other that will face the same notation challenges. A mechanism will need to be envisioned to support these use cases in future versions.

# Appendix I. Levels of Compliance

Due to the multiple use cases supported in this specification, it is not expected that all implementers can provide support to all the supported features from ProForma version 2. To facilitate adoption and separate some of the use cases, there are multiple “levels of compliance” and extensions for ProForma. The technical name of the level of compliance is indicated between parenthesis to enable labelling future software.

1) Base Level Support (Technical name: Base-ProForma Compliant)

Represents the lowest level of compliance, this level involves providing support for:

- Amino acid sequences

- Protein modifications using two of the supported CVs/ontologies: Unimod and PSI-MOD.

- Protein modifications using delta masses (without prefixes)

- N-terminal, C-terminal and labile modifications.

- Ambiguity in the modification position, including support for localisation scores.

- Ambiguity in the amino acid sequence.

- INFO tag.

2) Additional Separate Support (Technical name: level 2-ProForma compliant)

These features are independent from each other:

- Unusual amino acids (O and U).

- Ambiguous amino acids (e.g. X, B, Z). This would include support for sequence tags of known mass (using the character X).

- Protein modifications using delta masses (using prefixes for the different CVs/ontologies).

- Use of prefixes for Unimod (U:) and PSI-MOD (M:) names.

- Support for the joint representation of experimental data and its interpretation.

3) Top-Down Extensions (Technical name: level 2-ProForma + top-down compliant)

- Additional CV/ontologies for protein modifications: RESID (the prefix R MUST be used for RESID CV/ontology term names)

- Chemical formulas (this feature occurs in two places in this list).

4) Cross-Linking Extensions (Technical name: level 2-ProForma + cross-linking compliant)

- Cross-linked peptides (using the XL-MOD CV/ontology, the prefix X MUST be used for XL-MOD CV/ontology term names).

5) Glycan Extensions (Technical name: level 2-ProForma + glycans compliant)

- Additional CV/ontologies for protein modifications: GNO (the prefix G MUST be used for GNO CV/ontology term names)

- Glycan composition.

- Chemical formulas (this feature occurs in two places in this list).

6) Spectral Support (Technical name: level 2-ProForma + mass spectrum compliant)

- Charge and chimeric spectra are special cases (see Appendix II).

- Global modifications (e.g., every C is C13).

If one implementation supports more than one extension, multiple supported extensions can be indicated separated by ‘+’). Example: (level 2-ProForma + cross-linking + mass spectrum compliant).

Additionally, see Section 5 “Pending Issues - Future developments” for features not yet formally supported in this version of the specification. In the future, there could be additional extensions, e.g., for lipid molecules.

# Appendix II: Extensions to improve the representation of PSMs in mass spectra

This appendix is not relevant for the representation of peptidoforms and proteoforms, but rather presents techniques for representing PSMs (that is, peptidoforms and proteoforms together with mass spectra).

## **Representation of the ion charges**

The charge value MAY be optionally indicated in the C-terminal end of the amino acid sequence, by using the forward slash (/) character. Examples:

EMEVEESPEK/2

EM[U:Oxidation]EVEES[U:Phospho]PEK/3

[U:iTRAQ4plex]-EM[U:Oxidation]EVNES[U:Phospho]PEK[U:iTRAQ4plex]-[U:Methyl]/3

By default, a positive number n will imply a molecular ion that is n-times protonated

SEQUENCE/2 Means [SEQUENCE(neutral) + 2 protons ] and is doubly charged: [M+2H+]2+

By default, a negative number n will imply a molecular ion that is n-times deprotonated

SEQUENCE/-2 Means [SEQUENCE(neutral) - 2 protons ] and is doubly charged: [M-2H+]2-

When the charge derives from the addition or the removal of another ion, this ionic species SHOULD be provided after the charge state number. Examples include a Na+ adduct, the addition of one electron, the removal of a OH-, the addition of an iodine ion, and a radicalisation.

EMEVEESPEK/2[+2Na+,+H+]

EMEVEESPEK/1[+2Na+,-H+]

EMEVEESPEK/-2[2I-]

EMEVEESPEK/-1[+e-]

## **Representation of multiple peptidoform assignments in chimeric spectra**

In bottom-up approaches, in the case of chimeric spectra, more than one peptidoform sequence MAY be potentially assigned to a single mass spectrum. In this case, multiple peptidoform sequences MUST be separated by the plus sign (+). Example:

EMEVEESPEK/2+ELVISLIVER/3

# Appendix III. Glossary of terms used in the specification

The objective here is to provide a list of the keys used in the document, so that a summary view is available for implementers.

1- Protein modifications

1.1- (Non-labile) protein modifications are represented by using brackets [] + CV/ontology parameter names (for PSI-MOD/ Unimod).

For RESID (R:), XL-MOD (X:) and GNO (G:), extra prefixes MUST be used before the CV parameter names. For PSI-MOD (M:) and Unimod (U:), they are optional.

EM[Oxidation]EVEES[Phospho]PEK

EM[R: Methionine sulfone]EVEES[O-phospho-L-serine]PEK

EMEVTK[X:DSS#XL1]SESPEK (see Section 4.2.3)

EM[U:Oxidation]EVEES[U:Phospho]PEK

1.2- Non-labile protein modifications can also be reported using brackets [] including +/- Delta mass values.

EM[+15.9949]EVEES[+79.9663]PEK

The use of prefixes for reporting delta masses coming from ontologies/CVs MAY be supported (only in Advanced mode).

EM[U:+15.995]EVEES[U:+79.966]PEK

Experimentally observed delta masses are reported using the prefix [Obs:].

EM[U:+15.995]EVEES[Obs:+79.978]PEK

1.3- Sequence gaps of known mass MAY also be indicated using the amino acid X + brackets [] including the delta mass value of the tag.

RTAAX[+367.0537]WT

1.4- (Labile) protein modifications are indicated at the left side of the sequence using curly brackets {}.

{Glycan:Hex}EM[Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]

1.5- N-terminal and C-terminal modifications are indicated using a dash (-) on the left/right part of the sequence, respectively.

[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK

[iTRAQ4plex]-EM[Oxidation]EVNES[Phospho]PEK[iTRAQ4plex]-[Methyl]

1.6- Representation of global fixed modifications uses the “at” (@) character.

<[S-carboxamidomethyl-L-cysteine]@C>ATPEILTCNSIGCLK

<[MOD:01090]@C>ATPEILTCNSIGCLK

2- Ambiguity in the modification position:

2.1- Unknown modification positions can be indicated with the sign ‘?’.

[Phospho]?EM[Oxidation]EVTSESPEK

[Phospho][Phospho]?[Acetyl]-EM[Oxidation]EVTSESPEK

2.2- Groups of modifications can be linked using arbitrary labels. The preferred location for the modification is indicated by the actual position of the modification tag or name in the amino acid sequence. Scores on the modification position can be indicated using parentheses. Any annotation made with the symbol # represents a way of linking different locations within the amino acid sequence. In ProForma 2.0 it is used for representing cross-linkers, branched peptides and for grouping protein modifications (including glycans) to represent ambiguity.

EM[Oxidation]EVT[#g1]S[#g1]ES[Phospho#g1]PEK

EM[Oxidation]EVT[#g1(0.01)]S[#g1(0.09)]ES[Phospho#g1(0.90)]PEK

2.3- The cases reported in 6.1 and 6.2 can be combined to represent scores of the modification position.

[Phospho#s1]?EM[Oxidation]EVT[#s1(0.01)]S[#s1(0.90)]ES[#s1(0.90)]PEK

2.4- A range of positions for a modification can be indicated in the amino acid sequence using a parenthesis for those amino acids involved.

PROT(EOSFORMS)[+19.0523]ISK

PROT(EOC[Carbamidomethyl]FORMS)[+19.0523]ISK

3- Chemical formulas of small molecules may be specified using the descriptor [Formula:].

3.1- A formula will be composed of pairs of atoms and their corresponding cardinality. Pairs MAY be separated by spaces.

SEQUEN[Formula:C12H20O2]CE

3.2- Cardinalities must be a positive or negative integer values. Zero is not supported. If a cardinality is not included with an atom, it is assumed to be +1.

SEQUEN[Formula:HN-1O2]CE

3.3- Isotopes will be handled by prefixing the atom with its isotopic number in square brackets.

Here, 2 12C atoms are replaced by 2 13C atoms:

SEQUEN[Formula:[13C2][12C-2]H2N]CE (here 2 12C atoms are replaced by 2 13C atoms)

4- Glycan residues (generic monosaccharides) can be represented using the descriptor

“Glycan”[Glycan:].

SEQUEN[Glycan:HexNAc]CE

5- Cross-Linked Peptides and branched peptides

Using the XL-MOD CV, crosslinked sites MUST be represented immediately after the modification notation using the prefix #xl, followed by an arbitrary label consisting of alphanumeric characters ([A-Za-z0-9]+ in regular expression notation). Cross-linker modification notations MUST be mentioned once only. As mentioned above, any annotation made with the symbol # represents a way of linking different locations within the amino acid sequence. In ProForma 2.0 it is used for representing cross-linkers, and for grouping protein modifications (including glycans) to represent ambiguity.

EMEVTK[XLMOD:02001#XL1]SESPEK[#XL1]

“Dead end” crosslink: EMEVTK[XLMOD:02001#XL1]SESPEK

Inter-protein or inter-chain connections are supported using // to separate the crosslinked peptides.

SEK[XLMOD:02001#XL1]UENCE//EMEVTK[XLMOD:02001#XL1]SESPEK

Branched peptides can be expressed using the same notation used for representing two cross-linked peptides, but using the term #BRANCH.

a) ETFGD[MOD:00093#BRANCH]//R[#BRANCH]ATER

6- Representation of ambiguity in the amino acid sequence. This mechanism can be used to represent changes that do not change the mass of the peptidoform/proteoform, but are not known. The way to encode this information is to use a parenthesis and a quotation mark including the ambiguous sequence represented in a preferred way.

(?DQ)NGTWEM[Oxidation]ESNENFEGYM[Oxidation]K

7- Joint representation of experimental data and its interpretation uses the pipe “|” character.

ELVIS[Phospho|+79.966331]K

ELVIS[Phospho|Obs:+79.978]K

8- INFO Tag. The information represented in between an INFO tag is considered non-standard (e.g. any text except a close bracket character) and does not need to be parsed. It is equivalent to a #comment in source code. They can be split using the pipe character.

ELV[INFO:xxxxx]IS

ELVIS[Phospho|INFO:newly discovered|INFO:really awesome]K

“Info” tags can be used to provide metadata about the ProForma entities.

ELVIS[Phospho|INFO:newly discovered|INFO:Created on 2021-06]K

ELVIS[Phospho|INFO:newly discovered|INFO:Created by software Tool1]K

9- Representation of isotopes: They can be represented using <> including the concrete isotope in between.

<13C>ATPEILTVNSIGQLK

10- Representation of mass spectra features:

10.1- Charges for spectra are indicated at the end of the sequence using /.

EMEVEESPEK/2

10.2 Chimeric spectra are indicated using the plus “+” character.

EMEVEESPEK+ELVISLIVER

EMEVEESPEK/2+ELVISLIVER/3

## 

# Authors Information

Juan Antonio Vizcaíno

European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridge, United Kingdom

[juan@ebi.ac.uk](mailto:juan@ebi.ac.uk)

Eric W. Deutsch

Institute for Systems Biology, Seattle WA, USA

[edeutsch@systemsbiology.org](mailto:edeutsch@systemsbiology.org)

Pierre-Alain Binz

CHUV Lausanne University Hospital, Lausanne, Switzerland

[Pierre-Alain.Binz@chuv.ch](mailto:Pierre-Alain.Binz@chuv.ch)

Ryan Fellers

Northwestern University, Evanston IL, USA

[ryan.fellers@northwestern.edu](mailto:ryan.fellers@northwestern.edu)

Anthony J. Cesnik

Stanford University, Stanford CA, USA

[cesnik@stanford.edu](mailto:cesnik@stanford.edu)

Joshua A. Klein

Boston University, Boston MA, USA

[joshua.adam.klein@gmail.com](mailto:joshua.adam.klein@gmail.com)

Tim Van Den Bossche

Ghent University, Ghent, Belgium; VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium

[Tim.VanDenBossche@ugent.be](mailto:Tim.VanDenBossche@ugent.be)

Ralf Gabriels

Ghent University, Ghent, Belgium; VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium

[ralf.gabriels@ugent.be](mailto:ralf.gabriels@ugent.be)

Yasset Perez-Riverol

European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridge, United Kingdom

[yperez@ebi.ac.uk](mailto:yperez@ebi.ac.uk)

Jeremy Carver

University of California San Diego, San Diego CA, USA

[jcarver@ucsd.edu](mailto:jcarver@ucsd.edu)

Shin Kawano

Toyama University of International Studies, Toyama, Japan

[kawano@tuins.ac.jp](mailto:kawano@tuins.ac.jp)

Benjamin Pullman

University of California San Diego, San Diego CA, USA

[bpullman@eng.ucsd.edu](mailto:bpullman@eng.ucsd.edu)

Nuno Bandeira

University of California San Diego, San Diego CA, USA

[bandeira@ucsd.edu](mailto:bandeira@ucsd.edu)

Paul M. Thomas

Northwestern University, Evanston IL, USA

[paul-thomas@northwestern.edu](mailto:paul-thomas@northwestern.edu)

Richard Leduc

Northwestern University, Evanston IL, USA

[richard.leduc@northwestern.edu](mailto:richard.leduc@northwestern.edu)

# Contributors

In addition to the authors, a number of additional contributions have been made during the preparation process. The contributors who actively participated to the recommendation documentation are:

- Brian L. Frey, University of Wisconsin-Madison, Madison, WI, USA

- Alexander Leitner, ETH Zurich, Zurich, Switzerland

- Luis Mendoza, Institute for Systems Biology, Seattle, WA, USA

- Gerben Menschaert, Ghent University, Ghent, Belgium

- Jim Shofstahl, Thermo Fisher Scientific, San Jose, CA, USA

- Zhi Sun, Institute for Systems Biology, Seattle, WA, USA

- Leah V. Schaffer, University of Wisconsin-Madison, Madison, WI, USA

- Michael R. Shortreed, University of Wisconsin-Madison, Madison, WI, USA

- Veit Schwämmle, University of Southern Denmark, Odense, Denmark

- Wout Bittremieux, University of California San Diego, San Diego CA, USA

We would also like to acknowledge the contributions of the peer reviewers that participated in the PSI review process:

- Gloria Sheynkman and Erin Jeffery (University of Virginia, VA, USA).

- Xiaowen Liu (Tulane University School of Medicine, LA, USA).

Finally, we are also appreciative of the contributions made by the Executive Board of the CDTP, led by Paul Danis.

# Intellectual Property Statement

The PSI takes no position regarding the validity or scope of any intellectual property or other rights that might be claimed to pertain to the implementation or use of the technology described in this document or the extent to which any license under such rights might or might not be available; neither does it represent that it has made any effort to identify any such rights. Copies of claims of rights made available for publication and any assurances of licenses to be made available, or the result of an attempt made to obtain a general license or permission for the use of such proprietary rights by implementers or users of this specification can be obtained from the PSI Chair.

The PSI invites any interested party to bring to its attention any copyrights, patents or patent applications, or other proprietary rights which may cover technology that may be required to practice this recommendation. Please address the information to the PSI Chair (see contacts information at PSI website).

# Copyright Notice

Copyright (C) Proteomics Standards Initiative (2022). All Rights Reserved.

This document and translations of it may be copied and furnished to others, and derivative works that comment on or otherwise explain it or assist in its implementation may be prepared, copied, published and distributed, in whole or in part, without restriction of any kind, provided that the above copyright notice and this paragraph are included on all such copies and derivative works. However, this document itself may not be modified in any way, such as by removing the copyright notice or references to the PSI or other organizations, except as needed for the purpose of developing Proteomics Recommendations in which case the procedures for copyrights defined in the PSI Document process must be followed, or as required to translate it into languages other than English.

The limited permissions granted above are perpetual and will not be revoked by the PSI or its successors or assigns.

This document and the information contained herein is provided on an "AS IS" basis and THE PROTEOMICS STANDARDS INITIATIVE DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY THAT THE USE OF THE INFORMATION HEREIN WILL NOT INFRINGE ANY RIGHTS OR ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE."

# Glossary

All non-standard terms are already defined in detail in section 3.

# References

1. LeDuc, R.D., Schwammle, V., Shortreed, M.R., Cesnik, A.J., Solntsev, S.K., Shaw, J.B., Martin, M.J., Vizcaino, J.A., Alpi, E., Danis, P. *et al.* (2018) ProForma: A Standard Proteoform Notation. *Journal of proteome research*, 17, 1321-1325.

2. https://topdownproteomics.github.io/ProteoformNomenclatureStandard/.

3. Smith, L., Kelleher, N. The Consortium for Top Down Proteomics (2013) Proteoform: a single term describing protein complexity. *Nature Methods,* 10, 186–187

4. Binz, P.A., Shofstahl, J., Vizcaino, J.A., Barsnes, H., Chalkley, R.J., Menschaert, G., Alpi, E., Clauser, K., Eng, J.K., Lane, L. *et al.* (2019) Proteomics Standards Initiative Extended FASTA Format. *Journal of proteome research*, 18, 2686-2692.

5. Rosenberger, G., Liu, Y., Rost, H.L., Ludwig, C., Buil, A. Bensimon, A., Soste, M., Spector, T.D., Dermitzakis, E.T., Collins, B.C. *et al.* (2017) Inference and quantification of peptidoforms in large sample cohorts by SWATH-MS. *Nature Biotechnology*, 35(8):781-788.

6. Lermyte, F., Tsybin, Y.O., O’Connor, P.B. Loo, J.A. (2019) Top or Middle? Up or Down? Toward a Standard Lexicon for Protein Top-Down and Allied Mass Spectrometry Approaches. *Journal of the American Society of Mass Spectrometry*, 30(7):1149-1157.